1. Home
  2. DOMO vs MOLN Comparison

DOMO vs MOLN Comparison

Compare DOMO & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Domo Inc. Class B

DOMO

Domo Inc. Class B

HOLD

Current Price

$3.69

Market Cap

171.6M

Sector

Technology

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$3.74

Market Cap

144.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
DOMO
MOLN
Founded
2010
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
171.6M
144.0M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
DOMO
MOLN
Price
$3.69
$3.74
Analyst Decision
Buy
Buy
Analyst Count
9
2
Target Price
$10.28
$8.38
AVG Volume (30 Days)
692.6K
2.0K
Earning Date
05-20-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
31.92
N/A
EPS
N/A
N/A
Revenue
$318,857,000.00
N/A
Revenue This Year
$3.41
N/A
Revenue Next Year
$4.72
$374.07
P/E Ratio
N/A
N/A
Revenue Growth
0.57
N/A
52 Week Low
$2.39
$3.41
52 Week High
$18.49
$5.36

Technical Indicators

Market Signals
Indicator
DOMO
MOLN
Relative Strength Index (RSI) 52.12 32.97
Support Level $3.34 $3.52
Resistance Level $4.11 $3.97
Average True Range (ATR) 0.24 0.09
MACD -0.02 -0.05
Stochastic Oscillator 49.32 3.70

Price Performance

Historical Comparison
DOMO
MOLN

About DOMO Domo Inc. Class B

Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: